▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3611 by analyst upside · 2026-08-13
REGN
Regeneron Pharmaceuticals, Inc.
Healthcare · Market Cap $82B · P/E 19.7x
ANALYST PRICE TARGET
+4.5%
implied upside to consensus target
Current Price $797.99
Consensus Target $833.54
Bull Target $1030.0
Bear Target $641.0
Analysts Covering 27
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
14
Hold
9
Sell
0
52-Week Low $541.0
52-Week High $821.11
YTD Return +3.1%
FUNDAMENTALS
Market Cap $82B
P/E Ratio (TTM) 19.7x
Forward P/E 13.3x
EPS (TTM) $40.46
PEG Ratio 1.37
Dividend Yield 0.47%
Revenue (TTM) $15.5B
Profit Margin 27.9%
52-WEEK RANGE
52-Week Low $541.0
52-Week High $821.11
Current Price $797.99
Bear Target $641.0
Bull Target $1030.0
● Now $797.99 ● Target $833.54
TRADING DATA
Avg Volume 1.0M
YTD Return +3.1%
Analyst Count 27
Consensus Buy
Upside to Target +4.5%
Last Updated 2026-08-13

ANALYST SUMMARY

Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $797.99 with a Wall Street consensus price target of $833.54, implying potential upside of 4.5% over the next 12 months. 27 analysts currently cover REGN, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1030.0, while the most cautious has a target of $641.0.

REGN operates in the Healthcare sector with a market capitalisation of $82B. The stock is up 3.1% year-to-date and is currently trading near the upper end of its 52-week range of $541.0 – $821.11.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELV +12.5%
Elevance Health, Inc.
$87B · P/E 17.3x · Buy
HCA +9.6%
HCA Healthcare, Inc.
$90B · P/E 13.8x · Buy
BSX +21.9%
Boston Scientific Corporation
$75B · P/E 20.8x · Buy
MCK +12.8%
McKesson Corporation
$102B · P/E 24.2x · Buy
CI +23.1%
The Cigna Group
$73B · P/E 11.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for REGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-05-19 Building track record
BMO Capital - Reiterated
Outperform → Outperform 2026-05-18 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-05-18 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-18 43% win rate (7 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-18 14% win rate (7 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-18 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-18 Building track record
Citigroup ↓ Downgrade
Buy → Neutral 2026-05-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
25/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →